05 April 2019
Visiongain has published a new pharma report Top 25 Translational Regenerative Medicine Manufacturers 2019: Medtronic, Acelity, Integra Lifesciences, NuVasive, Orthofix International, Anika Therapeutics, Organogenesis, UniQure, TiGenix, Vericel Corporation, Other Companies.
In 2018, the global translational regenerative medicine is estimated at $28bn. The global translational regenerative medicine market is highly competitive and fragmented with the presence of several vendors. The competition is likely to increase with advances in R&D and technological innovations. The market is characterized by the presence of well-diversified international and local vendors that provide cost-effective products with limited features and functionalities.
This report profiled the selected companies: Medtronic, Acelity, Integra Lifesciences, NuVasive, Orthofix International, Anika Therapeutics, Organogenesis, UniQure, TiGenix, Vericel Corporation and other companies.
The lead analyst commented that "Advancements in biological sciences have shown a positive influence on the regenerative medicine market. There are new technological advancements in terms of drug manufacturing, development, and delivery. Many cell therapy products based on mesenchymal stem cells are available in the market because of their self-renewal ability and their presence in almost all tissues. The discovery of novel scaffolds and various growth and control factors have shown promising results in stimulating tissue formation. This has led to a shift in the focus to regenerative therapies over conventional methods of treatment."
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.
25 June 2019
Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.
21 June 2019
There is an increasing focus to identify diseases that currently do not have a vaccine.
20 June 2019
The market for ophthalmic drugs is a growing one.